Tian Rui, Ma Huilong, Yang Qinglai, Wan Hao, Zhu Shoujun, Chandra Swati, Sun Haitao, Kiesewetter Dale O, Niu Gang, Liang Yongye, Chen Xiaoyuan
Laboratory of Molecular Imaging and Nanomedicine , National Institute of Biomedical Imaging and Bioengineering (NIBIB) , National Institutes of Health (NIH) , Bethesda , Maryland 20892 , USA . Email:
Department of Materials Science & Engineering , Shenzhen Key Laboratory of Printed Organic Electronics , South University of Science & Technology of China , Shenzhen 518055 , China . Email:
Chem Sci. 2018 Oct 10;10(1):326-332. doi: 10.1039/c8sc03751e. eCollection 2019 Jan 7.
molecular imaging in the "transparent" near-infrared II (NIR-II) window has demonstrated impressive benefits in reaching millimeter penetration depths with high specificity and imaging quality. Previous NIR-II molecular imaging generally relied on high hepatic uptake fluorophores with an unclear mechanism and antibody-derived conjugates, suffering from inevitable nonspecific retention in the main organs/skin with a relatively low signal-to-background ratio. It is still challenging to synthesize a NIR-II fluorophore with both high quantum yield and minimal liver-retention feature. Herein, we identified the structural design and excretion mechanism of novel NIR-II fluorophores for NIR-II molecular imaging with an extremely clean background. With the optimized renally excreted fluorophore-peptide conjugates, superior NIR-II targeting imaging was accompanied by the improved signal-to-background ratio during tumor detection with reducing off-target tissue exposure. An unprecedented NIR-II imaging-guided microsurgery was achieved using such an imaging platform, which provides us with a great preclinical example to accelerate the potential clinical translation of NIR-II imaging.
在“透明”的近红外二区（NIR-II）窗口进行的分子成像已显示出在实现毫米级穿透深度方面具有令人印象深刻的优势，具备高特异性和成像质量。以往的NIR-II分子成像通常依赖于肝脏摄取高的荧光团，其机制不明，以及抗体衍生的缀合物，在主要器官/皮肤中存在不可避免的非特异性滞留，信号背景比相对较低。合成具有高量子产率和最小肝脏滞留特性的NIR-II荧光团仍然具有挑战性。在此，我们确定了用于NIR-II分子成像的新型NIR-II荧光团的结构设计和排泄机制，背景极其干净。通过优化的经肾脏排泄的荧光团-肽缀合物，在肿瘤检测过程中，优异的NIR-II靶向成像伴随着信号背景比的提高，同时减少了非靶向组织暴露。使用这样的成像平台实现了前所未有的NIR-II成像引导显微手术，这为我们提供了一个很好的临床前实例，以加速NIR-II成像的潜在临床转化。
